ClinicalTrials.gov
public full text
Public Domain
A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
The primary objective is to evaluate the efficacy of CCX168 (avacopan) to induce and sustain remission in patients with active anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), when used in combination with cyclophosphamide followed by azathioprine, or in combination with rituximab.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis#899367
- Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis#812561
- Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens#1281470
- ToFAcitinib in Early Active Axial SpondyloarThritis:#830672
- Immune Monitoring Following B-cell Depletion in ANCA-associated Vasculitis#1104329
Record · ID 1371123
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive